RANIHIGH SIGNALFINANCIAL10-K

RANI eliminated going concern warnings and substantially improved its financial position with meaningfully higher current assets and reduced liabilities.

The removal of "substantial doubt regarding our ability to continue as a going concern" language represents a fundamental shift in the company's financial outlook and survival prospects. The dramatic increase in Class A shares outstanding (from 33.5M to 99.7M) suggests a significant capital raising event that has strengthened the balance sheet and provided the liquidity cushion management needed to remove going concern warnings.

Comparing 2026-03-26 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

RANI's financial profile improved markedly, with current assets growing substantially to $53.3M and total liabilities declining meaningfully to $17.1M, creating a much stronger balance sheet foundation. Operating performance also showed improvement with operating cash flow deficit narrowing to -$18.7M and R&D expenses declining 24% to $20.2M, suggesting more disciplined spending. The combination of stronger liquidity, reduced liabilities, and improved operational efficiency enabled management to remove the going concern qualification that previously clouded the company's prospects.

FINANCIAL STATEMENT CHANGES
Current Assets
Balance Sheet
+79.3%
$29.7M→$53.3M

Current assets grew 79.3% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-67.2%
$268K→$88K

Capex reduced 67.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Total Assets
Balance Sheet
+60%
$36.6M→$58.6M

Asset base grew 60% — expansion through organic growth, acquisitions, or capital deployment.

Revenue
P&L
+58.9%
$1.0M→$1.6M

Strong top-line growth of 58.9% — accelerating demand or successful expansion into new markets.

Total Liabilities
Balance Sheet
-48.4%
$33.1M→$17.1M

Liabilities reduced 48.4% — deleveraging improves balance sheet strength and financial flexibility.

Operating Cash Flow
Cash Flow
+47.3%
-$35.5M→-$18.7M

Operating cash flow surged 47.3% — exceptional cash generation, highest quality earnings signal.

Interest Expense
P&L
-42.6%
$5.0M→$2.9M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Current Liabilities
Balance Sheet
-36.3%
$19.9M→$12.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Operating Income
P&L
+28.1%
-$53.3M→-$38.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

R&D Expense
P&L
-24.3%
$26.7M→$20.2M

R&D spending cut 24.3% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-03-26
PRIOR — 2025-03-31
ADDED
As of February 28, 2026, the registrant ha d 99,721,927 shares of Class A common stock, $0.0001 par value per share, outstanding, 23,970,359 shares of Class B common stock, $0.0001 par value per share, outstanding and no shares of Class C common stock, $0.0001 par value per share, outstanding.
Certain holders of units of the registrant s consolidated subsidiary, Rani Therapeutics, LLC, who do not hold shares of the registrant s Class B common stock can exchange their units of Rani Therapeutics, LLC fo r 1,124,194 shares of the registrant s Class A common stock.
Management's Discussion and Analysis of Financial Condition and Results of Operations 99 Item 7A.
Our collaboration and license agreement with Chugai Pharmaceutical Co., Ltd.
may not be successful, and we may not realize the anticipated benefits of the collaboration.
+7 more — sign up free →
REMOVED
As of March 26, 2025, the registrant had 33,509,827 shares of Class A common stock, $0.0001 par value per share, outstanding, 23,971,852 shares of Class B common stock, $0.0001 par value per share, outstanding and no shares of Class C common stock, $0.0001 par value per share, outstanding.
Certain holders of units of the registrant s consolidated subsidiary, Rani Therapeutics, LLC, who do not hold shares of the registrant s Class B common stock can exchange their units of Rani Therapeutics, LLC for 1,229,630 shares of the registrant s Class A common stock.
Management's Discussion and Analysis of Financial Condition and Results of Operations 105 Item 7A.
There is substantial doubt regarding our ability to continue as a going concern.
We will need to raise additional funding, which may not be available on acceptable terms.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →